Related Experiment Videos
Pentoxifylline attenuates hypoxic-ischemic brain injury in immature rats
1Department of Pediatrics, Ansan Hospital, Korea University Medical Center, Ansan-Si, Kyongki-Do.
Insights
Pentoxifylline pretreatment significantly reduced brain damage from oxygen deprivation in newborn rats. This phosphodiesterase inhibitor shows promise for preventing hypoxic-ischemic brain injury in vulnerable infants.
Area of Science:
- Neuroscience
- Pharmacology
- Neonatal Research
Background:
- Inflammatory mediators play a key role in immature brain damage following ischemia.
- Pentoxifylline, a phosphodiesterase inhibitor, is known to reduce inflammatory factors like tumor necrosis factor-alpha and platelet-activating factor.
Purpose of the Study:
- To investigate the potential of pentoxifylline in attenuating hypoxic-ischemic brain injury in immature rats.
- To evaluate the efficacy of pentoxifylline as a neuroprotective agent in neonatal brain injury models.
Main Methods:
- Seven-day-old rats underwent induced hypoxia-ischemia.
- Pentoxifylline was administered either as a pretreatment before hypoxia-ischemia or post-treatment after the event.
- Brain injury severity was assessed via visual infarction evaluation and hemispheric area measurements.
Main Results:
- Pentoxifylline pretreatment (40 mg/kg/dose) dramatically decreased the incidence of cerebral infarction from 75% to 10%.
- Quantitative analysis of hemispheric areas corroborated the neuroprotective effects of pretreatment.
- Post-hypoxic-ischemic treatment with pentoxifylline showed only a minor reduction in cortical damage.
Conclusions:
- Phosphodiesterase inhibition with pentoxifylline is a potential strategy to mitigate neonatal hypoxic-ischemic brain injury.
- Pretreatment with pentoxifylline may be clinically relevant for infants at risk of cerebral ischemia, such as those undergoing cardiac surgery.
Abstract:
Inflammatory mediators are implicated in the pathogenesis of ischemic injury in immature brain. The phosphodiesterase inhibitor pentoxifylline inhibits production of tumor necrosis factor-alpha and platelet-activating factor. We hypothesized that pentoxifylline treatment would attenuate hypoxic-ischemic brain injury in immature rats. Seven-day-old rats (n = 79) underwent right carotid ligation, followed by hypoxia (FiO2 = 0.08). Rats received pentoxifylline immediately before and again after hypoxia (two doses, 25-150 mg/kg/dose, n = 34), or vehicle (n = 27). In separate experiments, rats received pentoxifylline treatment (40 mg/kg/dose, n = 8), or vehicle (n = 10) immediately and again 3 h after hypoxia-ischemia. Severity of injury was assessed 5 d later by visual evaluation of ipsilateral hemisphere infarction and by measurement of bilateral hemispheric cross-sectional areas. Pentoxifylline pretreatment reduced the incidence of liquefactive cerebral infarction, from 75% in controls to 10% with pentoxifylline, 40 mg/kg/dose (p<0.001, chi2 trend test). Quantification of hemispheric areas confirmed these findings. In contrast, posthypoxic-ischemic treatment with pentoxifylline resulted in only a modest reduction in cortical damage, without an overall reduction in incidence of infarction. Phosphodiesterase inhibition may be an effective strategy to use to decrease the severity of neonatal hypoxic-ischemic brain injury. Pretreatment regimens could be clinically relevant in settings in which an increased risk of cerebral ischemia can be anticipated, such as in infants undergoing surgery to correct congenital heart disease.